Vahanian & Associates Financial Planning Inc. lessened its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 13.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,132 shares of the biopharmaceutical company’s stock after selling 2,460 shares during […]
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month […]
Stonnington Group LLC grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 164.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,200 shares of the biopharmaceutical company’s stock after acquiring an additional 8,200 shares during the period. Stonnington Group […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $67.05 and last traded at $66.62, with a volume of 528773 shares. The stock had previously closed at $65.48. Wall Street Analysts Forecast Growth A number of analysts have recently weighed […]
Osterweis Capital Management Inc. grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 37.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 57,750 shares of the biopharmaceutical company’s stock after acquiring an additional 15,855 shares during the quarter. Osterweis Capital Management Inc. […]